Product Description
Revumenib is an orally bioavailable protein-protein interaction (PPI) inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) proteins, with potential antineoplastic activity. Upon oral administration, revumenib targets and binds to the nuclear protein menin, thereby preventing the interaction between the two proteins menin and MLL and the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of MLL-rearranged leukemic cells. The menin-MLL complex plays a key role in the survival, growth, transformation and proliferation of certain kinds of leukemia cells. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Revumenib)
Mechanisms of Action: MEN1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Breakthrough Therapy - Acute Leukemia|LeukemiaFast Track - Acute Leukemia|LeukemiaOrphan Drug - Acute Leukemia|Acute Myeloid Leukemia|Leukemia|Myeloid Leukemia *
Approval Status: Approved
Approved Countries: None
Approved Indications: None
Company: Syndax
Company Location: Eastern America
Company Founding Year: 2005
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Czech Republic, France, Georgia, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Lithuania, Malaysia, Netherlands, Poland, Portugal, Puerto Rico, Romania, Serbia, Singapore, South Korea, Spain, Taiwan, Turkey, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 18
Recent & Upcoming Milestones
- Clinical Outcomes Expected - Syndax announced they will present P0 Acute Lymphoid Leukemia|Acute Myeloid Leukemia results on 2026-12-12 for Revumenib
- Clinical Outcomes Expected - Syndax announced they will present P1 Acute Leukemia results on 2026-12-13 for Revumenib
- Clinical Outcomes Expected - Syndax announced they will present P0 Acute Leukemia results on 2026-12-14 for Revumenib
Highest Development Phases
Phase 3: Acute Myeloid Leukemia
Phase 2: Acute Lymphoid Leukemia|Biphenotypic Acute Leukemia|Leukemia|Myelofibrosis|Polycythemia Vera|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Thrombocythemia, Essential
Phase 1: Acute Kidney Injury|Kidney Diseases|Lymphoid Leukemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07923071 |
SNDX-5613-0712 | P1 |
Not yet recruiting |
Acute Kidney Injury|Biphenotypic Acute Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Kidney Diseases|Acute Myeloid Leukemia|Acute Lymphoid Leukemia |
2030-01-01 |
44% |
2026-11-07 |
Primary Endpoints|Treatments |
NCT07283640 |
NCI-2025-09116 | P1 |
Not yet recruiting |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Lymphoid Leukemia |
2029-08-31 |
36% |
2025-12-17 |
Primary Endpoints|Treatments |
NCT06177067 |
RAVAML | P1 |
Recruiting |
Biphenotypic Acute Leukemia|Acute Myeloid Leukemia |
2027-01-01 |
31% |
2026-10-23 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
NCT07734077 |
MPN-RC 129 | P2 |
Not yet recruiting |
Myelofibrosis|Polycythemia Vera|Thrombocythemia, Essential |
2028-12-01 |
31% |
2026-07-30 |
Primary Endpoints|Treatments |
NCT06229912 |
NCI-2024-00534 | P2 |
Recruiting |
Leukemia |
2028-12-01 |
55% |
2026-09-12 |
Primary Completion Date|Primary Endpoints|Treatments |
NCT04065399 |
AUGMENT-101 | P2 |
Recruiting |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Biphenotypic Acute Leukemia |
2027-12-15 |
46% |
2026-02-18 |
|
NCT05360160 |
SAVE | P2 |
Recruiting |
Acute Myeloid Leukemia |
2026-12-01 |
38% |
2024-09-20 |
Primary Completion Date|Primary Endpoints |
2025-522279-27-00 |
SNDX-5613-0710 | P3 |
Not yet recruiting |
Acute Myeloid Leukemia |
2030-04-30 |
58% |
||
NCT03013998 |
The Beat AML Trial | P3 |
Recruiting |
Acute Myeloid Leukemia |
2032-12-01 |
52% |
2026-09-04 |
Primary Endpoints |
jRCT2051260190 |
jRCT2051260190 | P3 |
Not yet recruiting |
Acute Myeloid Leukemia |
2031-01-31 |
|||
NCT07211958 |
REVEAL-ND NPM1 | P3 |
Recruiting |
Acute Myeloid Leukemia |
2029-06-01 |
58% |
2026-09-26 |
Primary Endpoints|Treatments |
NCT07212023 |
REVEAL-ND KMT2A | P2 |
Not yet recruiting |
Acute Myeloid Leukemia |
2030-07-01 |
44% |
2025-10-09 |
Primary Endpoints|Treatments |
NCT06284486 |
NCI-2024-01721 | P2 |
Recruiting |
Acute Myeloid Leukemia |
2026-12-30 |
35% |
2025-05-22 |
Primary Endpoints|Treatments |
2024-513759-34-00 |
SNDX-5613-0700 | P2 |
Active, not recruiting |
Unknown |
2025-04-30 |
2025-05-02 |
Treatments |
|
NCT06313437 |
NCT06313437 | P1 |
Recruiting |
Acute Myeloid Leukemia |
2027-03-02 |
31% |
2026-03-26 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT06226571 |
SNDX-5613-0708 | P1 |
Active, not recruiting |
Acute Myeloid Leukemia |
2027-02-01 |
38% |
2026-09-17 |
Patient Enrollment|Primary Endpoints|Treatments |
NCT05406817 |
SNDX-5613-0705 | P1 |
Completed |
Unknown |
2024-11-18 |
40% |
2025-01-11 |
|
NCT05326516 |
AUGMENT-102 | P1 |
Completed |
Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2024-07-29 |
32% |
2024-08-14 |
Primary Endpoints |
